{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/60b1306d44938a0013db19cf/618146f9f2a3a0001420bc46?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"How the pandemic shifted Roche’s priorities and R&D investments ","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/60b1306d44938a0013db19cf/1623315228296-0f6d70af5a62181f19e3343e22b64ea2.jpeg?height=200","description":"<p>In this episode of Conversations in Healthcare, Mike Ward&nbsp;speaks with Richard Erwin, general manager and managing director of Roche Products Limited (UK), which was recorded in collaboration with One Nucleus's ON Helix conference&nbsp;(June 2021). Richard shares how the pandemic has shifted Roche’s priorities&nbsp;and why the organization has heavily increased their investment in R&amp;D. Learn more in the full episode.&nbsp;</p>","author_name":"Clarivate"}